We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cellavision AB (CEVI) Ord NPV

Sell:262.50 SEK Buy:264.00 SEK Change: 1.50 SEK (0.57%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:262.50 SEK
Buy:264.00 SEK
Change: 1.50 SEK (0.57%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:262.50 SEK
Buy:264.00 SEK
Change: 1.50 SEK (0.57%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

Contact details

Mobilvagen 12
223 62
+46 (46) 4601600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
6.31 billion SEK
Shares in issue:
23.85 million
Health Care Equipment
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Simon Oestergaard
    President, Chief Executive Officer
  • Magnus Blixt
    Chief Financial Officer
  • Urban Strindloev
    Vice President - Global Sales
  • Peter Wilson
    Vice President - Global Marketing
  • Adam Morell
    Vice President - Devices & Software Division
  • Julien Veyssy
    Vice President - Reagents Division
  • Jeppe Brandstrup
    Vice President - Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.